8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

August 7, 2008

Date of Report (Date of earliest event reported)

BIOLASE TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-19627	87-0442441
(State of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

4 Cromwell
Irvine, California 92618
(Address of principal executive offices) (Zip Code)

(949) 361-1200

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

EXHIBIT 99.1

Item 2.02 Results of Operations and Financial Condition

     On August 7, 2008, BIOLASE Technology, Inc. (“Biolase”) issued a press release announcing its financial results for the second quarter ended June 30, 2008. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     This Current Report on Form 8-K and the information contained in the press release shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K and the press release is not incorporated by reference into any filings of Biolase, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in the filing, unless explicitly incorporated by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

     (d) Exhibits.

99.1 Press Release of BIOLASE Technology, Inc., dated August 7, 2008.

2

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIOLASE TECHNOLOGY, INC.
Date: August 7, 2008	By:	/s/ Jake St. Philip
		Jake St. Philip
		Chief Executive Officer

3

EXHIBIT INDEX

Exhibit no.	Description
99.1	Press Release of BIOLASE Technology, Inc., dated August 7, 2008.

EX-99.1

Exhibit 99.1

NEWS RELEASE for August 7, 2008

BIOLASE REPORTS SECOND QUARTER, SIX-MONTH RESULTS

Second Consecutive Quarter of Profitability

IRVINE, CA (August 7, 2008) — BIOLASE Technology, Inc. (NASDAQ:BLTI), the world’s leading dental laser company, today reported operating results for its second quarter and first six months ended June 30, 2008.

Net revenue for this year’s second quarter and first six months was $18.7 million and $37.7 million, respectively, up from $18.2 million and $33.2 million in the respective prior year periods. Gross profit for the second quarter and first six months of 2008 increased $97,000 and $1.5 million, respectively. Gross margin as a percentage of sales decreased to 54 percent and 52 percent of net revenue as compared with 55 percent of net revenue for both the second quarter and first six months of 2007. Operating expenses in this year’s second quarter and first six months were $9.7 million and $19.9 million compared to operating expenses of $10.9 million and $20.9 million in the respective prior year periods. Net income for the second quarter of 2008 was $622,000, or $0.03 per share, compared with a net loss of $901,000, or $0.04 loss per share, in the same period of 2007. For this year’s first six months, net income was $648,000, or $0.03 per share, compared with a net loss of $2.6 million, or $0.11 loss per share.

Other income in this year’s second quarter and first six months increased $81,000 and $542,000 including a gain on foreign currency of $225,000 and $841,000, respectively, compared to a gain of $15,000 and $68,000 in the same periods of 2007.

BIOLASE Chief Executive Officer Jake St. Philip said the two consecutive quarters of profitability in a challenging economic environment were encouraging and that the Company continues to push forward on organizational initiatives designed to bring BIOLASE to a normalized pattern of growth and profitability. He also noted that the Company is pleased with the improved performance in the domestic markets, which was a major focus for the first six months, and has initiated short-term corrective actions and longer-term planning to improve what has been a disappointing performance in international markets.

“We believe our new strategy is sound and, while any new strategy takes time to gain traction, it will ultimately prove itself in the marketplace,” St. Philip said. “We have improved our relationship with Henry Schein, reorganized our domestic sales team and processes, and have a new emphasis on market segmentation and corresponding product development programs. Many of those programs are underway and the organization is responding well; cost controls continue to be strong and while we still anticipate somewhat uneven revenue growth in the near term, the team has made a great deal of progress toward our goals.”

In July, the quarter was capped off by the introduction of the Waterlase® C100, a product that rounds out the Company’s hard-tissue offering and provides a solution for practices that seek a device with fewer features than the Waterlase® MD at a lower price point. First customer deliveries of the new Waterlase C100 are expected to begin by the end of this year’s third quarter.

“While overall sales grew 3 percent year-over-year in the second quarter, Waterlase sales experienced a 7 percent decline due to weaker international performance. The summer months traditionally make the third quarter a more challenging one, so this is an ideal time for launching our new two-tiered product strategy. There may be some transitional impact of these changes in the third quarter, but we are confident in the long-term benefits of our strategy,” St. Philip added.

As of June 30, 2008, the balance sheet showed cash and cash equivalents of $14.5 million, total assets of $38.6 million and total stockholders’ equity of $18.6 million. As of June 30, 2008, the Company also paid off all of its outstanding debt, which totaled $3.6 million as of December 31, 2007 and $2 million as of March 31, 2008.

Conference Call

As previously announced, the Company will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the second quarter and first six months ended June 30, 2008 and to answer questions. Slides will be used during this call. Directions for accessing the slides can be found below.

Phone Participation

To listen to the conference call live via telephone, please dial 1-800-762-8908 from the U.S. or, for international callers, please dial +1-480-248-5085, approximately 10 minutes before the start time. In order to access the slides that will be used on the call, click on the link provided on the Investors section of the BIOLASE website at www.biolase.com to listen to the event, register and select the “No Audio, Slides Only” option.

Webcast Participation

To listen to the conference call live and view the slide presentation via the Internet, visit the Investors section of the BIOLASE website at www.biolase.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary software.

Replay

A telephone replay will be available for two days by dialing 1-800-406-7325 from the U.S., or +1-303-590-3030 for international callers, and entering passcode number 3904490. In addition, a replay will be available on BIOLASE’s website.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (http://www.biolase.com), the world’s leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company’s products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company’s actual results to differ materially from the statements contained herein, and are described in the Company’s reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

For further information, please contact: David M. Mulder, Chief Financial Officer of BIOLASE Technology, Inc., +1-949-361-1200; or Jill Bertotti, of Allen & Caron, +1-949-474-4300.

- TABLE FOLLOWS -

BIOLASE TECHNOLOGY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
(in thousands, except per share data)

	Three Months Ended June 30,						Six Months Ended June 30,
	2008			2007			2008			2007
Products and services revenue	$	17,795		$	17,148		$	35,832		$	31,248
License fees and royalty revenue		868			1,029			1,872			1,989
Net revenue		18,663			18,177			37,704			33,237
Cost of revenue		8,556			8,167			18,015			15,090
Gross profit		10,107			10,010			19,689			18,147
Operating expenses:
Sales and marketing		5,052			6,934			10,657			13,327
General and administrative		3,398			2,802			6,475			5,179
Engineering and development		1,271			1,197			2,732			2,407
Total operating expenses		9,721			10,933			19,864			20,913
Profit (loss) from operations		386			(923	)		(175	)		(2,766	)
Gain on foreign currency transactions		225			15			841			68
Interest income		26			126			84			278
Interest expense		(36	)		(7	)		(60	)		(23	)
Non-operating income, net		215			134			865			323
Income (loss) before income tax provision		601			(789	)		690			(2,443	)
Income tax (benefit) provision		(21	)		112			42			181
Net income (loss)	$	622		$	(901	)	$	648		$	(2,624	)
Net income (loss) per share:
Basic	$	0.03		$	(0.04	)	$	0.03		$	(0.11	)
Diluted	$	0.03		$	(0.04	)	$	0.03		$	(0.11	)
Shares used in the calculation of net income (loss) per share:
Basic		24,164			23,841			24,110			23,816
Diluted		24,358			23,841			24,326			23,816

BIOLASE TECHNOLOGY, INC.

CONSOLIDATED BALANCE SHEETS (Unaudited)
(in thousands, except per share data)

	June 30, 2008			December 31, 2007
ASSETS
Current assets:
Cash and cash equivalents	$	14,507		$	14,566
Accounts receivable, less allowance of $1,018 and $1,033 in 2008 and 2007, respectively		5,354			11,266
Inventory, net		9,340			7,627
Prepaid expenses and other current assets		1,288			2,317
Total current assets		30,489			35,776
Property, plant and equipment, net		3,805			4,040
Intangible assets, net		1,023			1,208
Goodwill		2,926			2,926
Deferred tax asset		65			50
Other assets		307			308
Total assets	$	38,615		$	44,308
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Line of credit	$	—		$	3,552
Accounts payable		7,208			6,151
Accrued liabilities		6,209			9,431
Deferred revenue, current portion		4,068			5,649
Total current liabilities		17,485			24,783
Deferred tax liabilities		379			342
Deferred revenue, long-term		1,778			2,236
Other liabilities, long-term		354			456
Total liabilities		19,996			27,817
Stockholders’ equity:
Preferred stock, par value $0.001, 1,000 shares authorized, no shares issued and outstanding		—			—
Common stock, par value $0.001, 50,000 shares authorized; 26,204 and 25,967 shares issued and 24,240 and 24,003 shares outstanding in 2008 and 2007, respectively		27			26
Additional paid-in capital		114,849			113,430
Accumulated other comprehensive gain		114			54
Accumulated deficit		(79,972	)		(80,620	)
		35,018			32,890
Treasury stock (cost of 1,964 shares repurchased)		(16,399	)		(16,399	)
Total stockholders’ equity		18,619			16,491
Total liabilities and stockholders’ equity	$	38,615		$	44,308